



Keri L. Schaubert, Ph.D.

Associate

New York

kschaubert@cozen.com | (212) 883-2258

Keri concentrates her practice on complex patent cases for clients in the pharmaceutical and biotechnology industries. She is a registered patent attorney and represents pharmaceutical companies in Hatch-Waxman and biosimilar litigation.

Prior to attending law school, Keri received her Ph.D. in immunology from Wayne State University School of Medicine where, as a part of her doctoral research, she studied human CD8+ T cell responses to HIV epitopes and mimotopes thereof. Keri then completed a postdoctoral fellowship at the University of Michigan where she examined the role of transforming growth factor- β (TGF- β) in natural killer (NK) cell maturation. Keri has been published in numerous immunology journals.

Keri is also a graduate of Loyola University Chicago School of Law, and earned a bachelor's degree in biology and anthropology from the University of Michigan.

Experience

Secured a verdict in favor of Kyowa Kirin, Inc., a specialty pharmaceutical company that currently markets three products in the United States, after a five-day bench trial in federal court in which the largest generic pharmaceutical company in the world challenged a patent covering the client's transdermal granisetron patch product. In securing this victory, we overcame the plaintiff's contentions that there was no infringement, that the patent at issue was invalid, and that the patent was unenforceable.

Represented Endo Pharmaceuticals Inc. and Strakan International S.à r.l. against Watson Labs' attempt to make a generic version of Endo's FORTESTA® product. Following a bench trial, the judge ruled in our clients' favor on all contested issues and rejected the defendant's claims of non-infringement, invalidity, and unenforceability. Successfully argued on appeal with the Federal Circuit affirming the trial court decision.

Represented Apotex Inc. and Apotex Corp. in a patent infringement action regarding Apotex's biosimilar applications to make biosimilar versions of Amgen's NEULASTA® and NEUPOGEN® products. We navigated Apotex through the Biologics Price Competition and Innovation Act's "patent dance," and in the first BPCIA case to go to trial, we obtained a verdict of noninfringement. This result was affirmed on appeal to the U.S. Court of Appeals for the Federal Circuit.

Practice Areas

- Biologics/Biosimilars
- Hatch-Waxman Litigation
- Intellectual Property
- Intellectual Property Litigation

Education

- Loyola University Chicago School of Law, J.D., 2013
- Wayne State University of Medicine, Ph.D., 2006
- University of Michigan, B.S., 2000

Bar Admissions

- Illinois
- United States Patent and Trademark Office

Keri L. Schaubert, Ph.D.

kschaubert@cozen.com

P: (212) 883-2258 | F: (212) 986-0604

©2019 Cozen O'Connor. All rights reserved.

